Commercializing biomedical research through securitization techniques

  title={Commercializing biomedical research through securitization techniques},
  author={J. Fern{\'a}ndez and Roger M. Stein and Andrew W. Lo},
  journal={Nature Biotechnology},
Biomedical innovation has become riskier, more expensive and more difficult to finance with traditional sources such as private and public equity. Here we propose a financial structure in which a large number of biomedical programs at various stages of development are funded by a single entity to substantially reduce the portfolio's risk. The portfolio entity can finance its activities by issuing debt, a critical advantage because a much larger pool of capital is available for investment in… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 64 times over the past 90 days. VIEW TWEETS
31 Citations
32 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 31 extracted citations


Publications referenced by this paper.
Showing 1-10 of 32 references

A 21–book review

  • Lo, A. W. Reading about the financial crisis
  • Journal of Economic Literature 50, 151–178
  • 2012

A survey of the health of the private sector

  • Huggett, B. Biotech’s wellspring
  • Nature Biotechnology 30, 395–400
  • 2012

Oncology clinical trials—secrets of success

  • D. Thomas
  • Biotech Now
  • 2012

Reading about the financial crisis : a 21 – book review

  • A. W. Lo
  • J . Econ . Lit .
  • 2012

Rethinking Finance: New Perspectives on the Crisis (Russell Sage Foundation

  • A. S. Blinder, A. W. Lo, R. M. Solow
  • New York,
  • 2012

Stelios papadopoulos

  • Papadopoulos, S. Profile
  • Nature Biotechnology 29, 184
  • 2012

Where have all the ipos gone

  • X. Gao, J. R. Ritter, Z. Zhu
  • 2012

Beyond Borders: Global Biotechnology

  • Ernst, Young
  • Report 2011 (Ernst and Young, New York,
  • 2011

Similar Papers

Loading similar papers…